The speed with which the court scheduled the case may reflect its awareness of the opioid problem.
The court, they said, will focus narrowly on the liability shield, an increasingly popular, though contentious, bankruptcy tactic.
“I’m sure, though, that even if the opioid crisis doesn’t show up anywhere in the opinion, the court has to be bearing in mind that cities, states and individuals have been desperately waiting for these funds.
Though numerous pharmaceutical companies have been sued for their roles in the opioid epidemic, the Sacklers and Purdue loom large in the story of the complex, decades-old crisis.
The steep fines did little to deter Purdue from continuing to aggressively market OxyContin.
Persons:
”, Adam Zimmerman, OxyContin
Organizations:
University of Southern California’s Gould School of Law, Purdue, Food and Drug Administration, Sackler